Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer
- 30 November 2009
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 66 (2), 176-183
- https://doi.org/10.1016/j.lungcan.2009.02.004
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Abrogation of the interaction between osteopontin and αvβ3 integrin reduces tumor growth of human lung cancer cells in miceLung Cancer, 2007
- Osteopontin Promotes Integrin Activation through Outside-In and Inside-Out Mechanisms: OPN-CD44V Interaction Enhances Survival in Gastrointestinal Cancer CellsCancer Research, 2007
- Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3Oncogene, 2006
- Osteopontin Expression and Prognostic Significance in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- A novel CYR61-triggered ‘CYR61-αvβ3 integrin loop’ regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathwayOncogene, 2004
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors*Journal of Cellular Biochemistry, 2002
- Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancersInternational Journal of Cancer, 1997
- Roles of Osteopontin in Bone RemodelingaAnnals of the New York Academy of Sciences, 1995
- Structural and Functional Domains of OsteopontinAnnals of the New York Academy of Sciences, 1995